Pneumococcal polysaccharide vaccine

This page covers all Pneumococcal polysaccharide vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Streptococcus pneumoniae capsular polysaccharides (23 serotypes).

Targets

Streptococcus pneumoniae capsular polysaccharides (23 serotypes)

Marketed (2)

• Investigational 23-valent PPV · Sinovac Biotech Co., Ltd · Immunology / Infectious Disease
  A 23-valent pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.
• Control 23-valent PPV · Sinovac Biotech Co., Ltd · Immunology / Infectious Disease
  This pneumococcal polysaccharide vaccine stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae, providing protection against pneumococcal disease.

Phase 3 pipeline (1)

• 23vPS · Wyeth is now a wholly owned subsidiary of Pfizer · Immunology / Infectious Disease
  23vPS is a 23-valent pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.